Acne vulgaris: A review of antibiotic therapy

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 3, 2005, Pages 409-418

  Tan, Audrey W ^a   Tan, Hiok Hee ^a  

^a NATIONAL SKIN CENTRE   (Singapore)

Author keywords

Acne vulgaris; Antimicrobial drug resistance; Macrolides; Propionibacterium acnes; Tetracyclines; Trimethoprim

Indexed keywords

ADAPALENE; ANTIBIOTIC AGENT; AZITHROMYCIN; BENZAMYCIN; BENZOYL PEROXIDE; CARBAMAZEPINE; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; DOXYCYCLINE HYCLATE; ERYTHROMYCIN; ISOTRETINOIN; LYMECYCLINE; MINOCYCLINE; ORAL CONTRACEPTIVE AGENT; OXYTETRACYCLINE; RETINOIC ACID; RETINOID DERIVATIVE; ROXITHROMYCIN; SULFAMETHOXAZOLE; SULFONAMIDE; SULFUR; TAZAROTENE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; TRIMETHOPRIM; UNINDEXED DRUG; WARFARIN; ZINC;

ABDOMINAL PAIN; ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CHOLESTATIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENAMEL HYPOPLASIA; EOSINOPHILIA; ESOPHAGITIS; ESOPHAGUS ULCER; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOMODULATION; LIVER DYSFUNCTION; LIVER FAILURE; LONG TERM CARE; LUPUS VULGARIS; MEDICAL DECISION MAKING; NAUSEA; NEUTROPHILIA; NONHUMAN; ONYCHOLYSIS; OTOTOXICITY; PANCREATITIS; PAPULE; PATIENT COMPLIANCE; PERCEPTION DEAFNESS; PHARYNGITIS; PHOTOSENSITIVITY; PHOTOTOXICITY; PHYSICIAN; PIGMENT DISORDER; PNEUMONIA; PRESCRIPTION; PROPIONIBACTERIUM ACNES; PSEUDOMEMBRANOUS COLITIS; REVIEW; SKIN DISEASE; SKIN INFLAMMATION; SKIN PIGMENTATION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TOOTH COLOR; TOOTH DISEASE; TOXIC EPIDERMAL NECROLYSIS; TREATMENT FAILURE; TREATMENT PLANNING; VAGINA CANDIDIASIS; VERTIGO; VESTIBULAR DISORDER; VOMITING;

ACNE VULGARIS; ADMINISTRATION, TOPICAL; ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; HUMANS; TETRACYCLINES; TRIMETHOPRIM; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 17144428978     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.3.409     Document Type: Review

References (78)

1. CHEN W, THIBOUTOT D, ZOUBOULIS CC: Cutaneous androgen metabolism: basic research and clinical perspectives. J. Invest. Dermatol. (2002) 119(5):992-1007.
2. MORELLO AM, DOWNING DT, STRAUSS JS: Octadecadienoic acids in the skin surface lipids of acne patients and normal subjects. J. Invest. Dermatol. (1976) 66(5):319-332.
3. GUY R, GREEN MR, KEALEY T: Modeling acne in vitro. J. Invest. Dermatol. (1996) 106(1):176-182.
4. THIBOUTOT D, HARRIS C, ILES V, CIMIS G, GILLILAND K, HAGARI S: Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J. Invest. Dermatol. (1995) 105(2):209-214.
5. TOYODA M, MOROHASHI M: New aspects in acne inflammation. Dermatology (2003) 206(1):17-23.
6. LEYDEN JJ, MCGINLEY KJ, MILLS OH, KLIGMAN AM: Propionibacterium levels in patients with and without acne vulgaris. J. Invest. Dermatol. (1975) 65(4):382-384.
7. BROWN SK, SHALITA A: Acne vulgaris. Lancet (1998) 351(9119):1871-1876.
8. VOWELS BR, YANG S, LEYDEN JJ: Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect. Immun. (1995) 63 8):3158-3165.
9. KIM J, OCHOA MT, KRUTZIK SR et al.: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J. Immunol. (2002) 169(3):1535-1541.
10. GRAHAM GM, FARRAR MD, CRUSE-SAWYER JE, HOLLAND KT, INGHAM E: Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br. J. Dermatol. (2004) 150(3):421-428.
11. MEYNADIER J, ALIREZAI M: Systemic antibiotics for acne. Dermatology (1998) 196(1):135-139.
12. NEWTON JN, MALLON E, KLASSEN A, RYAN TJ, FINLAY AY: The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. Br. J. Dermatol. (1997) 137(4):563-567.
13. CUNLIFFE WJ, VAN DE KERKHOF PC, CAPUTO R et al.: Roaccutane treatment guidelines: results of an international survey. Dermatology (1997) 194(4):351-357.
14. HAIDER A, SHAW J: Treatment of acne vulgaris. JAMA (2004) 292(6):726-735.
15. EADY EA: Bacterial resistance in acne. Dermatology (1998) 196(1):59-66.
16. COATES P, ADAMS CA, CUNLIFFE WJ: Does oral isotretinoin prevent Propionibacterium acnes resistance? Dermatology (1997) 195(Suppl. 1):4-9.
17. EADY EA, JONES CE, GARDNER KJ, TAYLOR JP, COVE JH, CUNLIFFE WJ: Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline, but sensitive to minocycline. Br. J. Dermatol. (1993) 128(5):556-560.
18. ROSS JI, SNELLING AM, EADY EA et al.: Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br. J. Dermatol. (2001) 144(2):339-346.
19. OZOLINS M, EADY EA, AVERY AJ et al.: Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet (2004) 364(9452):2188-2195.
20. GOLLNICK H, CUNLIFFE WJ, BERSON D et al.: Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J. Am. Acad. Dermatol. (2003) 49(1 Suppl.):S1-S37.
21. LEYDEN JJ, MCGINLEY KJ, KLIGMAN AM: Tetracycline and minocycline treatment. Arch. Dermatol. (1982) 118(1):19-22.
22. AL-MOFARREH MA, AL MOFLEH IA: Esophageal ulceration complicating doxycycline therapy. World J. Gastroenterol. (2003) 9(3):609-611.
23. LEE AG: Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne. Cutis (1995) 55(30):165-168.
24. HARRISON PV: A comparison of doxycycline and minocycline in the treatment of acne vulgaris. Clin. Exp. Dermatol. (1988) 13 4):242-244.
25. LAYTON AM, CUNLIFFE WJ: Phototoxic eruptions due to doxycycline - a dose-related phenomenon. Clin. Exp. Dermatol. (1993) 18(5):425-427.
26. SKIDMORE R, KOVACH R, WALKER C et al.: Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch. Dermatol. (2003) 139(4):459-464.
27. DEL ROSSO JO: A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis (2004) 74 2):118-122.
28. CHOSIDOW O, POLI F, NALINE E, ADVENIER C, REVUZ J: Comedonal diffusion of minocycline in acne. Dermatology (1998) 196 1):162.
29. GOLDEN V, GLASS D, CUNLIFFE WJ: Safety of long-term minocycline in the treatment of acne. Br. J. Dermatol. (1996) 134(4):693-695.
30. GOUGH A, CHAPMAN S, WAGSTAFF K, EMERY P, ELIAS E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. Br. Med. J. (1996) 312(7024):169-172.
31. SITBON O, BIDEL N, DUSSOPT C et al.: Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch. Intern. Med. (1994) 154(14):1633-1640.
32. GOOD ML, HUSSEY DL: Minocycline: stain devil? Br. J. Dermatol. (2003) 149(2):237-239.
33. PEPINE M, FLOWERS FP, RAMOS-CARO FA: Extensive cutaneous hyperpigmentation caused by minocycline. J. Am. Acad. Dermatol. (1993) 28(2 Pt 2):292-295.
34. BUTLER JM, MARKS R, SUTHERLAND R: Cutaneous and cardiac valvular pigmentation with minocycline. Clin. Exp. Dermatol. (1985) 10(5):432-437.
35. SILLER GM, TOD MA, SAVAGE NW: Minocycline-induced oral pigmentation. J. Am. Acad. Dermatol. (1994) 30(2 Pt 2):350-354.
36. MOUTON RW, JORDAAN HF, SCHNEIDER JW: A new type of minocycline-induced cutaneous hyperpigmentation. Clin. Exp. Dermatol. (2004) 29(1):8-14.
37. THIBAULT MJ, BILLICK RC, SROLOVITZ H: Minocycline-induced Sweet's syndrome. J. Am. Acad. Dermatol. (1992) 27(5 Pt 2):801-804.
38. KHAN DURANI B, JAPPE U: Drug-induced Sweet's syndrome in acne caused by different tetracyclines: case report and review of the literature. Br. J. Dermatol. (2002) 147(3):558-562.
39. GRIM SA, ROMANELLI F, JENNINGS PR, OFOTOKUN I: Late-onset drug fever associated with minocycline: case report and review of the literature. Pharmacotherapy (2003) 23(12):1659-1562.
40. TAN HH: Antibacterial therapy for acne. Am. J. Clin. Dermatol. (2003) 4(5):307-314.
41. SCHLIENGER RG, BIRCHER AJ, MEIER CR: Minocycline-induced lupus. A systematic review. Dermatology (2000) 200 3):223-231.
42. GROSSHANS E, BELAICH S, MEYNADIER J, ALIREZAI M, THOMAS L: A comparison of the efficacy and safety of lymecycline and minocycline in patients with moderately severe acne vulgaris. Eur. J. Dermatol. (1998) 8(3):161-166.
43. BOSSUYT L, BOSSCHAERT J, RICHERT B et al.: Lymecycline in the treatment of acne: an efficacious, safe and cost-effective alternative to minocycline. Eur. J. Dermatol. (2003) 13 2):130-135.
44. CUNLIFFE WJ, MEYNADIER J, ALIREZAI M et al.: Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. J. Am. Acad. Dermatol. (2003) 49 3 Suppl.):S218-S226.
45. GAMMON WR, MEYER C, LANTIS S, SHENEFELT P, REIZNER G, CRIPPS DJ: Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris: a double-blind study. J. Am. Acad. Dermatol. (1986) 14(2 Pt 1):183-186.
46. EADY EA, GLOOR M, LEYDEN JJ: Propionibacterium acnes resistance: a world wide problem. Dermatology (2003) 206 1):54-56.
47. ROSS JI, SNELLING AM, CARNEGIE E et al.: Antibiotic-resistant acne: lessons from Europe. Br. J. Dermatol. (2003) 148(3):467-478.
48. TAN HH: Antibiotic sensitivity of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann. Acad. Med. Singapore (2001) 30(1):22-25.
49. BRUMMETT RE: Ototoxic liability of erythromycin and analogues. Otolaryngol. Clin. North. Am. (1993) 26 5):811-819.
50. DERBY LE, JICK H, HENRY DA, DEAN AD: Erythromycin-associated cholestatic hepatitis. Med. J. Aust. (1993) 158(9):600-602.
51. FANG CC, WANG HP, LIN JT: Erythromycin-induced acute pancreatitis. J. Toxicol. Clin. Toxicol. (1996) 34(1):93-95.
52. WROBLEWSKI BA, SINGER WD, WHYTE J: Carbamazepine-erythromycin interaction. Case studies and clinical significance. JAMA (1986) 255(9):1165-1167.
53. TENENBEIN M: Theophylline toxicity due to drug interaction. J. Emerg. Med. (1989) 7(3):249-251.
54. WELLS PS, HOLBROOK AM, CROWTHER NR et al.: Interactions of warfarin with drugs and food. Ann. Intern. Med. (1994) 121 9):676-683.
55. AKAMATSU H, TOMITA T, HORIO T: Effects of roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology (2002) 204(4):277-280.
56. FERAHBAS A, UTAS S, AYKOL D, BORLU M, UKSAL U: Clinical evaluation of roxithromycin: a double-blind, placebo-controlled and crossover trial in patients with acne vulgaris. J. Dermatol. (2004) 31(1):6-9.
57. EASTON-CARTER KL, HARDIKAR W, SMITH AL: Possible roxithromycin-induced fulminant hepatic failure in a child. Pharmacotherapy (2001) 21(7):867-870.
58. KAPADIA N, TALIB A: Acne treated successfully with azithromycin. Int. J. Dermatol. (2004) 43(10):766-767.
59. EADY EA, JONES CE, TIPPER JL, COVE JH, CUNLIFFE WJ, LAYTON AM: Antibiotic resistant propionibacteria in acne; need for policies to modify antibiotic usage. Br. Med. J. (1993) 306 6877):555-556.
60. NORDIN K, HALLANDER H, FREDRIKSSON T, RYLANDER C: A clinical and bacteriological evaluation of the effect of sulphamethoxazole-trimethoprim in acne vulgaris, resistant to prior therapy with tetracyclines. Dermatologica (1978) 157 4):245-253.
61. BOTTOMLEY WW, CUNLIFFE WJ: Oral trimethoprim as a third-line antibiotic in the management of acne vulgaris. Dermatology (1993) 187(3):193-196.
62. CUNLIFFE WJ, ALDANA OL, GOULDEN V: Oral trimethoprim: a relatively safe and successful third-line treatment for acne vulgaris. Br. J. Dermatol. (1999) 141(4):757-758.
63. LAYTON AM: Optimal management of acne to prevent scarring and psychological sequelae. Am. J. Clin. Dermatol. (2001) 2 3):135-141.
64. THIBOUTOT D: New treatments and therapeutic strategies for acne. Arch. Fam. Med. (2000) 9(2):179-187.
65. PARRY MF, RHA CK: Pseudomembranous colitis caused by topical clindamycin phosphate. Arch. Dermatol. (1986) 122(5):583-584.
66. LEYDEN JJ: Antibiotic resistance in the topical treatment of acne vulgaris. Cutis (2004) 73(6S):6-10.
67. SCHACHNER L, PESTANA A, KITTLES C: A clinical trial comparing the safety and efficacy of a topical erythromycin-zinc formulation with a topical clindamycin formulation. J. Am. Acad. Dermatol. (1990) 22(3):489-495.
68. EADY EA, FARMERY MR, ROSS JI, COVE JH, CUNLIFFE WJ: Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and -resistant skin bacteria from acne patients. Br. J. Dermatol. (1994) 131(3):331-336.
69. EADY EA, BOJAR RA, JONES CE, COVE JH, HOLLAND KT, CUNLIFFE WJ: The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br. J. Dermatol. (1996) 134(1):107-113.
70. BOJAR RA, CUNLIFFE WJ, HOLLAND KT: The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br. J. Dermatol. (1995) 132 204-208.
71. TAN HH: Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am. J. Clin. Dermatol. (2004) 5(2):79-84.
72. LEYDEN JJ, MCGINLEY KJ, CAVALIERI S, WEBSTER GF, MILLS OH, KLIGMAN AM: Propionibacterium acnes resistance to antibiotics in acne patients. J. Am. Acad. Dermatol. (1983) 8(1):41-45.
73. COOPER AJ: Systematic review of Propionibacterium acnes resistance to systemic antibiotics.Med. J. Aust. (1998) 169 5):259-261.
74. HARPER J: An update on the pathogenesis and management of acne vulgaris. J. Am. Acad. Dermatol. (2004) 51(1 Suppl.):S36-S38.
75. MCCORMACK WM, GEORGE H, DONNER A et al.: Hepatotoxicity of erythromycin estolate during pregnancy. Antimicrob. Agents Chemother. (1977) 12(5):630-635.
76. KATSAMBAS AD, KATOULIS AC, STAVROPOULOS P: Acne neonatorum: a study of 22 cases. Int. J. Dermatol. (1999) 38(2):128-130.
77. CUNLIFFE WJ, BARON SE, COULSON IH: A clinical and therapeutic study of 29 patients with infantile acne. Br. J. Dermatol. (2001) 145(3):463-466.
78. SIMPSON N: Antibiotics in acne: time for a rethink. Br. J. Dermatol. (2001) 144(2):225-228.